Keyphrases
30-day Mortality
100%
Activity Concentration
14%
Activity Level
100%
Adult Cardiac Surgery
12%
Adult Patients
100%
Anaphylactic Reaction
12%
Anti-Xa Level
14%
Aortic Dissection
25%
Aortic Endocarditis
12%
Aprotinin
100%
Bleeding
12%
Bolus
57%
Bolus Administration
28%
Bolus Injection
14%
Bypass Grafting
75%
Cardiac Surgery
100%
Continuous Intravenous Infusion
100%
Coronary Artery Bypass Grafting
100%
Creatinine
12%
Dialysis
12%
Dual Antiplatelet Therapy
12%
Endocarditis
12%
Enoxaparin
100%
EuroSCORE II
100%
Finland
12%
High-risk Adults
100%
High-risk Cardiac Surgery
12%
In-hospital Mortality
12%
Infusion Administration
100%
Low Molecular Weight Heparin
14%
Low Risk
14%
Non-isolated
37%
Nordic Countries
100%
Norway
12%
Patient Demographics
14%
Patient Registry
25%
Pharmacological Thromboprophylaxis
14%
Prospective Randomized Trial
14%
Randomized Clinical Trial
100%
Randomized Controlled Clinical Trial
14%
Registry Data
12%
Resternotomy
12%
Route of Administration
14%
Safety Endpoints
12%
Safety Profile
12%
Subcutaneous Administration
100%
Surgery Department
12%
Sweden
12%
Thromboprophylaxis
14%
Trough Concentration
14%
Pharmacology, Toxicology and Pharmaceutical Science
Anaphylaxis
12%
Antiplatelet
12%
Aortic Dissection
25%
Aprotinin
100%
Bioavailability
10%
Bleeding
12%
Blood Clotting Factor 10
100%
Controlled Clinical Trial
10%
Coronary Risk
10%
Creatinine
12%
Endocarditis
25%
Enoxaparin
100%
Hospital Mortality
12%
Low Molecular Weight Heparin
10%
Mortality Rate
100%
Patient Registry
25%
Randomized Clinical Trial
100%
Subcutaneous Injection
100%
Thromboembolism
12%
Medicine and Dentistry
Anaphylaxis
12%
Antiplatelet
12%
Aortic Dissection
25%
Aprotinin
100%
Bleeding
12%
Creatinine
12%
Endocarditis
25%
EuroSCORE
100%
Grafting
75%
Heart Surgery
37%
Hospital Mortality
12%
Median Sternotomy
12%
Mortality Rate
100%
Patient Registry
25%
Thromboembolism
12%
